This is the text extract for 2010-06 Schedule Dispatch, browse documents here.

18 May 2010

June 2010 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the June 2010 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

New listings · Enalapril (Arrow-Enalapril) tab 5 mg (p’code: 2358794), 10 mg (p’code: 2358808) and 20 mg (p’code: 2358816) · Nandrolone decanoate (Deca-Durabolin Orgaject) inj 50 mg per ml, 1 ml – Retail pharmacy–Specialist – Section 29 (p’code: 2353865) · Tramadol hydrochloride (Arrow-Tramadol) cap 50 mg (p’code: 2351889) · Cytarabine (Pfizer) inj 500 mg (p’code: 2359510) and 1 g (p’code: 2359529) – Retail pharmacy–Specialist · Cytarabine (Pfizer) inj 2 g – PCT only - Specialist (p’code: 2359537) · Irinotecan (Irinotecan-Rex) inj 20 mg per ml, 2 ml (p’code: 2351005) and inj 20 mg per ml, 5 ml (p’code: 2351013) · Mitomycin-C (Arrow) inj 5 mg – PCT only – Specialist – Section 29 (p’code: 2358832) Changes to restrictions · Pancreatic enzyme (Cotazym ECS, Creon 10000, Creon Forte, Panzytrat) cap – removal of Retail pharmacy–Specialist restriction · Ferrous sulphate (Ferodan) oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) – amended presentation · Malathion (Derbac-M) liq 0.5% – addition of Original Pack (OP) status · Combined oral contraceptives – removal of delisted brand names in Special Authority criteria · Progesterone-only contraceptives – removal of delisted brand names in Special Authority criteria · Alendronate for osteoporosis – amended Special Authority criteria · Naltrexone hydrochloride (ReVia) tab 50 mg – amended Special Authority criteria · Cytarabine (Pfizer, Mayne) inj 500 mg, 1 g and 2 g – amended presentation · Cytarabine (Baxter) inj 1 mg for ECP – amended of unit of measure Decreased subsidy

Chemical Presentation Fully brands subsidised Partially subsidised brands Coloxyl

Docusate sodium Risperidone

Tab 50 mg and 120 mg Tab 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg

Cytarabine Vincristine sulphate

Inj 100 mg Inj 1 mg per ml, 2 ml Inj 1 mg for ECP

Laxofast 50 and 120 Ridal*, Risperdal, Apo-Risperidone and Dr Reddy’s Risperidone Pfizer, Mayne Hospira Baxter

* The Ridal brand is the only brand with a subsidy and price change via reference pricing from 1 June 2010.

A355830 Page 1 of 2

Increased subsidy

Chemical Cytarabine Vincristine sulphate Presentation Inj 1 mg for ECP Inj 1 mg per ml, 1 ml Fully brands Baxter Hospira subsidised

NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.

Fixing the Niggles PHARMAC has an ongoing strategy of, where possible, amending the Pharmaceutical Schedule to reduce unnecessary administrative burden for pharmacists. One recent example of this includes addition of OP status to malathion liquid (this month). If you notice any other area that you feel may be improved upon, please do not hesitate to contact us on 0800 66 00 50.

A355830 Page 2 of 2